Factor VIII inhibitor with catalytic activity towards factor VIII

Haematologica

Volumn 85, Issue 10 SUPPL., 2000, Pages 89-92

  Lacroix Desmazes, S ^a   Sooryanarayana, ^a   Moreau, A ^a   Kazatchkine, M D ^a   Kaveri, S V ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Catalytic antibodies; Factor VIII; FVIII inhibitor; Hemophilia

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; CATALYTIC ANTIBODY;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; BLEEDING; CLINICAL FEATURE; CONFERENCE PAPER; HEMOPHILIA A; HUMAN; PATHOGENESIS; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; ANTIBODIES, CATALYTIC; BINDING SITES; FACTOR VIII; HEMOPHILIA A; HUMANS; KINETICS; PEPTIDE FRAGMENTS;

EID: 0033695026     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
2. Inhibitor incidence in French previously untreated patients (PUPS) with severe hemophilia A receiving recombinant factor VIII. One year additional exposure to rFVIII
3. The molecular genetic analysis of haemophilia A; characterization of six partial deletions in the factor VIII gene
4. Haemophilia A: Mutation type determines risk of inhibitor formation
5. 365 of the factor VIII heavy chain
6. Identification of a FVIII epitope recognized by a human hemophilic inhibitor
7. Molecular basis of factor VIII inhibition by human antibodies: Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid
8. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
9. A role for the C2 domain of factor VIII in binding to von Willebrand factor
10. Some human inhibitor antibodies interfere with factor VIII binding to factor IX
11. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
12. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for FVIII inhibition
13. Nature of forces between large molecules of biological interest
14. Hapten design for the generation of catalytic antibodies
15. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody
16. Cleavage of vasoactive intestinal peptide at multiple sites by autoantibodies
17. Vasoactive intestinal peptide hydrolysis by antibody light chains
18. DNA hydrolyzing autoantibodies
19. Cleavage of supercoiled plasmid DNA by autoantibody Fab fragment: Application of the flow linear dichroism technique
20. Natural catalytic antibodies: Peptide-hydrolyzing activities of Bence Jones proteins and VL fragments
21. Phosphorylation of different human milk proteins by human catalytic secretory immunoglobulin A
22. Catalytic activity of anti-thyroglobulin antibodies
23. Catalytic activity of antibodies against factor VIII in patients with hemophilia A
24. Inactivation of factor VIII by factor IXa
25. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa
26. Distribution of factor VIII mRNA and antigen in human liver and other tissues
27. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor
28. Site specificity of a catalytic vasoactive intestinal peptide antibody
29. DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases
30. Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease
31. A more uniform measurement of factor VIII inhibitors